FX.co ★ Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. (DYN) announced promising results on Friday from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101, targeting patients with myotonic dystrophy type 1 (DM1). Myotonic dystrophy type 1 is a genetic disorder characterized by the progressive weakening and loss of muscle function. The company reported that the study results demonstrate a significant impact of DYNE-101 on crucial disease biomarkers. Dyne is planning to commence a Registrational Expansion Cohort in the ACHIEVE trial, with a submission for accelerated approval anticipated in the first half of 2026.